Prescription Drug Price Hikes Help Fuel Massive 32 Percent Boost to Profits For Big Pharma Giant As millions of Americans struggle to afford the medications they need, the first earnings report from a Big Pharma giant demonstrates the industry continues to rake in sky-high profits by shamelessly hiking prices. Just yesterday, brand name drug […]
Lawmakers Hold Strong, Advance Trade Deal Without Big Pharma-Backed Provision on Biologic Exclusivity Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) applauded U.S. Senators Thursday who voted to approve the revised U.S.-Mexico-Canada Agreement (USMCA) without a provision that would have helped brand name drug companies undermine competition and keep prices high for American […]
Editorial Boards, Lawmakers and More Reiterate Need for Market-Based Solutions to Out-of-Control Prescription Drug Prices in 2020 Right on cue, Big Pharma kicked off the New Year by raising prices on 2,167 prescription drugs in the first week of 2020. The new round of price hikes have added to the momentum to pass bipartisan market-based […]
News from First Weeks of New Year Underscores Urgent Need for Action in Congress In case you missed it, Big Pharma has hiked prices on 2,167 prescription drugs so far this year – proving once again that without legislative action, brand name drug makers will continue to price-gouge American patients. Among the companies hiking prices […]
Drug Makers, Including Brand Name Giants Like Pfizer, Increase Prices on More Than 200 Prescription Drugs Despite Mounting Crisis of Affordability Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Thursday in response to a new analysis which found drug makers, including brand name giants Pfizer, GlaxoSmithKline and Sanofi, rung in […]
Passage of Bipartisan, Market-based CREATES Act Will Be A First Step in the Right Direction But Patients Need Washington to Do Much More Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) commended Congress for including the bipartisan, market-based Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act in a spending deal announced […]
CMS Report Demonstrates Impact of Out-of-Control Launch Prices and Tactics That Prevent Patients From Accessing Affordable Alternatives In case you missed it, according to the Centers for Medicare and Medicaid Services’ (CMS) annual report on health care spending, the pricing practices and anti-competitive tactics of Big Pharma kept drug costs rising last year — even […]
Passage of HR3 Adds to Momentum to Hold Big Pharma Accountable; Now Congress Must Move Swiftly to Get Bipartisan Reforms Passed into Law Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) commended lawmakers in the U.S. House for passing market-based reforms included in the Elijah E. Cummings Lower Drug Costs Now Act (HR3) Thursday […]
Revisions to Historic Trade Deal Remove Big Pharma Carveout Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) commended the White House and lawmakers in the U.S. House for removing provisions from the U.S.-Mexico-Canada Agreement (USMCA) that were supported by Big Pharma and that would have helped brand name drug makers undermine competition and […]
Corporate Filings Show Drug Makers Boosted Payouts for Shareholders 17 Times More Than Increased Investment in ‘Innovation’ Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released an analysis Tuesday that found brand name prescription drug manufacturers used a windfall from the Tax Cuts and Jobs Act of 2017 to line shareholders’ pockets, rather […]